{"product_id":"vascular-targeted-therapies-in-oncology-hardback-9780470012949","title":"Vascular-Targeted Therapies in Oncology (Hardback) 9780470012949","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eVascular-Targeted Therapies in Oncology\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cfont size=\"4\"\u003eDietmar W. Siemann (Edited by), DW Siemann (Author)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780470012949, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 17 March 2006\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e368 pages\u003cbr\u003e24.9 x 17.6 x 2.9 cm, 0.822 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cem\u003e\u003cfont size=\"3\"\u003e\"A Multi-Author text describing techniques of targeting the abnormal vasculature of tumours by drugs. ... This is cutting-edge clinical science.\" (\u003ci\u003e2007 BMA Medical Book Competition Programme and Award Winners)\u003c\/i\u003e\u003c\/font\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e\u003ci\u003e\u003cb\u003eVascular-Targeted Therapies in Oncology\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAttacking a tumor's supportive blood vessel network may offer novel means of improving cancer cure rates. The vasculature is critical to tumor development, survival, growth and metastatic spread. However, tumor blood vessels are abnormal, both morphologically and functionally, and display characteristics that distinguish them from normal vasculature. It is these inherent differences between blood vessels associated with tumors and those associated with normal tissues that provide a variety of unique targets for the design of novel therapeutics and treatment strategies highly selective for the cancer.\u003c\/p\u003e \u003cp\u003eVascular-disrupting strategies aim to cause a rapid and catastrophic shutdown in the established vessel networks of solid tumors. This arrests the blood flow and induces tumor cell death as a result of oxygen and nutrient deprivation and build up of waste products. Biological vascular-disrupting approaches include targeted gene therapy, antibodies to neovascular antigens and ligand-directed therapies targeting endothelial cell receptors and extracellular matrix proteins. Small molecule drug approaches have focused primarily on flavenoids and tubulin-binding agents. This book examines the fundamental bases of both these approaches. Emphasis is placed on target development, preclinical assessment, use in combination with conventional treatment regimens and the current clinical status of these therapies.\u003c\/p\u003e \u003cp\u003eThis book is intended for cancer researchers and clinical oncologists. Its goal is to review the potential of vascular-targeting strategies in cancer management and to foster an understanding of the key differences between these therapeutic approaches and conventional anticancer treatments. Though more research is required to establish the clinical efficacy and ideal application of vascular-disrupting strategies, this developing anticancer approach continues to generate great research interest and clinical optimism.\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003ePreface xiii\u003c\/p\u003e \u003cp\u003eList of Contributors xv\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Tumor Vasculature: A Target for Anticancer Therapies 1\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eDietmar W. Siemann\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction 1\u003c\/p\u003e \u003cp\u003e1.2 Tumor vasculature 1\u003c\/p\u003e \u003cp\u003e1.3 Impact of tumor microenvironments on cancer management 2\u003c\/p\u003e \u003cp\u003e1.4 Vascular-targeting therapies 3\u003c\/p\u003e \u003cp\u003e1.5 Combinations with conventional anticancer therapies 4\u003c\/p\u003e \u003cp\u003e1.6 Combinations of antiangiogenic and vascular-disrupting agents 5\u003c\/p\u003e \u003cp\u003e1.7 Conclusions 5\u003c\/p\u003e \u003cp\u003eAcknowledgments 6\u003c\/p\u003e \u003cp\u003eReferences 6\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Abnormal Microvasculature and Defective Microcirculatory Function in Solid Tumors 9\u003cbr\u003e \u003c\/b\u003e\u003ci\u003ePeter Vaupel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 9\u003c\/p\u003e \u003cp\u003e2.2 Basic principles of blood vessel formation in tumors 10\u003c\/p\u003e \u003cp\u003e2.3 Tumor lymphangiogenesis 13\u003c\/p\u003e \u003cp\u003e2.4 Tumor vascularity and blood flow 13\u003c\/p\u003e \u003cp\u003e2.5 Volume and composition of the tumor interstitial space 17\u003c\/p\u003e \u003cp\u003e2.6 Fluid pressure and convective currents in the interstitial space of tumors 18\u003c\/p\u003e \u003cp\u003e2.7 Evidence, characterization and pathogenesis of tumor hypoxia 18\u003c\/p\u003e \u003cp\u003e2.8 Tumor pH 23\u003c\/p\u003e \u003cp\u003e2.9 The ‘crucial Ps’ characterizing the hostile metabolic microenvironment of solid tumors 25\u003c\/p\u003e \u003cp\u003eAcknowledgment 27\u003c\/p\u003e \u003cp\u003eReferences 27\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 The Role of Microvasculature in Metastasis Formation 31\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eOliver Stoeltzing and Lee M. Ellis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 31\u003c\/p\u003e \u003cp\u003e3.2 Regulators of angiogenesis in solid tumors 34\u003c\/p\u003e \u003cp\u003e3.3 Angiogenesis and metastasis formation 47\u003c\/p\u003e \u003cp\u003e3.4 Summary 53\u003c\/p\u003e \u003cp\u003eReferences 53\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Development of Agents that Selectively Disrupt Tumor Vasculature: a Historical Perspective 63\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eDavid J. Chaplin and Sally A. Hill\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 63\u003c\/p\u003e \u003cp\u003e4.2 Early history 65\u003c\/p\u003e \u003cp\u003e4.3 Formulation of the VDA concept 67\u003c\/p\u003e \u003cp\u003e4.4 Effects of vascular occlusion on tumor cell survival 68\u003c\/p\u003e \u003cp\u003e4.5 Rational development of VDA therapeutics 68\u003c\/p\u003e \u003cp\u003e4.6 Development of small-molecule VDAs 70\u003c\/p\u003e \u003cp\u003e4.7 Combretastatin A4 phosphate 73\u003c\/p\u003e \u003cp\u003e4.8 The viable rim 76\u003c\/p\u003e \u003cp\u003e4.9 Conclusions 76\u003c\/p\u003e \u003cp\u003eReferences 77\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Morphologic Manifestations of Vascular-Disrupting Agents in Preclinical Models 81\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMumtaz V. Rojiani and Amyn M. Rojiani\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction 82\u003c\/p\u003e \u003cp\u003e5.2 Animal models 82\u003c\/p\u003e \u003cp\u003e5.3 Morphologic and morphometric analysis 84\u003c\/p\u003e \u003cp\u003e5.4 Effects of treatment 85\u003c\/p\u003e \u003cp\u003eAcknowledgments 92\u003c\/p\u003e \u003cp\u003eReferences 92\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Molecular Recognition of the Colchicine Binding Site as a Design Paradigm for the Discovery and Development of Vascular Disrupting Agents 95\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eKevin G. Pinney\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introductory comments 95\u003c\/p\u003e \u003cp\u003e6.2 Colchicine binding site on tubulin 96\u003c\/p\u003e \u003cp\u003e6.3 Brief overview of tubulin biology 97\u003c\/p\u003e \u003cp\u003e6.4 Small-molecule inhibitors of tubulin assembly 100\u003c\/p\u003e \u003cp\u003e6.5 Design paradigm for small-molecule vascular disrupting agents 105\u003c\/p\u003e \u003cp\u003e6.6 Concluding remarks 113\u003c\/p\u003e \u003cp\u003eAcknowledgments 114\u003c\/p\u003e \u003cp\u003eReferences 114\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Combined Modality Approaches Using Vasculaturedisrupting Agents 123\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eWenyin Shi, Michael R. Horsman and Dietmar W. Siemann\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Tumor vasculature 123\u003c\/p\u003e \u003cp\u003e7.2 Vascular-disrupting strategies 124\u003c\/p\u003e \u003cp\u003e7.3 VDAs and chemotherapy 125\u003c\/p\u003e \u003cp\u003e7.4 VDAs and radiation therapy 128\u003c\/p\u003e \u003cp\u003e7.5 VDAs and antiangiogenic agents 131\u003c\/p\u003e \u003cp\u003e7.6 Summary 131\u003c\/p\u003e \u003cp\u003eAcknowledgments 132\u003c\/p\u003e \u003cp\u003eReferences 132\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Vasculature-targeting Therapies and Hyperthermia 137\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMichael R. Horsman and Rumi Murata\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction 137\u003c\/p\u003e \u003cp\u003e8.2 Enhancing hyperthermia 140\u003c\/p\u003e \u003cp\u003e8.3 Enhancing thermoradiotherapy 148\u003c\/p\u003e \u003cp\u003e8.4 Conclusions and clinical relevance 151\u003c\/p\u003e \u003cp\u003eAcknowledgments 152\u003c\/p\u003e \u003cp\u003eReferences 152\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Flavones and Xanthenones as Vascular-disrupting Agents 159\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eBronwyn G. Siim and Bruce C. Baguley\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Development of FAA and DMXAA 159\u003c\/p\u003e \u003cp\u003e9.2 Antivascular activity of FAA and DMXAA 161\u003c\/p\u003e \u003cp\u003e9.3 Cytokine induction by FAA and DMXAA 162\u003c\/p\u003e \u003cp\u003e9.4 Molecular target 163\u003c\/p\u003e \u003cp\u003e9.5 Preclinical studies: DMXAA as a single agent 164\u003c\/p\u003e \u003cp\u003e9.6 Preclinical studies: combination treatments 165\u003c\/p\u003e \u003cp\u003e9.7 Species differences 169\u003c\/p\u003e \u003cp\u003e9.8 Clinical studies 171\u003c\/p\u003e \u003cp\u003eReferences 172\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Targeting Inside-Out Phospholipids on Tumor Blood Vessels in Pancreatic Cancer 179\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eAdam W. Beck, Rolf Brekken and Philip E. Thorpe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Vascular targeting 179\u003c\/p\u003e \u003cp\u003e10.2 Pancreatic cancer: the clinical need 180\u003c\/p\u003e \u003cp\u003e10.3 Phosphatidylserine 181\u003c\/p\u003e \u003cp\u003e10.4 Proof of concept studies 183\u003c\/p\u003e \u003cp\u003e10.5 Combined treatment with 3G4 and gemcitabine in a pancreatic cancer model 185\u003c\/p\u003e \u003cp\u003e10.6 Mechanism of action 188\u003c\/p\u003e \u003cp\u003e10.7 Conclusion 191\u003c\/p\u003e \u003cp\u003eReferences 191\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Cadherin Antagonists as Vasculature-targeting Agents 195\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eOrest Blaschuk and Tracey M. Rowlands\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Pericytes as regulators of blood vessel stability 195\u003c\/p\u003e \u003cp\u003e11.2 Cadherins 196\u003c\/p\u003e \u003cp\u003e11.3 Cadherins and the vasculature 197\u003c\/p\u003e \u003cp\u003e11.4 Tumor vasculature 199\u003c\/p\u003e \u003cp\u003e11.5 Manipulation of the tumor vasculature with cadherin antagonists 200\u003c\/p\u003e \u003cp\u003e11.6 Summary and future directions 201\u003c\/p\u003e \u003cp\u003eAcknowledgment 201\u003c\/p\u003e \u003cp\u003eReferences 201\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Alphastatin: a Pluripotent Inhibitor of Activated Endothelial Cells 205\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eCarolyn A. Staton and Claire Lewis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction 205\u003c\/p\u003e \u003cp\u003e12.2 Discovery of alphastatin 207\u003c\/p\u003e \u003cp\u003e12.3 Development of alphastatin 210\u003c\/p\u003e \u003cp\u003e12.4 Conclusions 218\u003c\/p\u003e \u003cp\u003eReferences 218\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Cationic Lipid Complexes to Target Tumor Endothelium 221\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eUwe Michaelis and Michael Teifel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 221\u003c\/p\u003e \u003cp\u003e13.2 Tumor vascular targeting by cationic liposomes 222\u003c\/p\u003e \u003cp\u003e13.3 Potential targets for cationic lipid complexes on tumor endothelial cells 225\u003c\/p\u003e \u003cp\u003e13.4 Cationic liposomes as drug carriers 227\u003c\/p\u003e \u003cp\u003e13.5 Side-effects of intravenously administered cationic lipid complexes 230\u003c\/p\u003e \u003cp\u003e13.6 Preclinical data 232\u003c\/p\u003e \u003cp\u003e13.7 Clinical data 238\u003c\/p\u003e \u003cp\u003e13.8 Conclusion 239\u003c\/p\u003e \u003cp\u003eAcknowledgments 240\u003c\/p\u003e \u003cp\u003eReferences 240\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Development of Vasculature-targeting Cancer Gene Therapy 247\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eGraeme J. Dougherty, Peter D. Davis and\u003cbr\u003e Shona T. Dougherty\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Introduction 247\u003c\/p\u003e \u003cp\u003e14.2 Advantages of tumor vasculature as a target in cancer gene therapy 248\u003c\/p\u003e \u003cp\u003e14.3 Genes of value in vascular-targeted cancer gene therapy 249\u003c\/p\u003e \u003cp\u003e14.4 Targeting gene therapy to tumor vasculature 249\u003c\/p\u003e \u003cp\u003e14.5 Concluding remarks 256\u003c\/p\u003e \u003cp\u003eAcknowledgment 256\u003c\/p\u003e \u003cp\u003eReferences 257\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Vasculature-disrupting Strategies Combined with Bacterial Spores Targeting Hypoxic Regions of Solid Tumors 261\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eG-One Ahn and J. Martin Brown\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 Hypoxia and necrosis as a selective target for cancer therapy 261\u003c\/p\u003e \u003cp\u003e15.2 Use of Clostridia as hypoxia\/necrotic selective cancer therapy 262\u003c\/p\u003e \u003cp\u003e15.3 Advantage of CDEPT over ADEPT and GDEPT 265\u003c\/p\u003e \u003cp\u003e15.4 Combination of CDEPT with vascular-disrupting agents 267\u003c\/p\u003e \u003cp\u003e15.5 Clinical significance 272\u003c\/p\u003e \u003cp\u003eReferences 273\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Imaging the Effects of Vasculature-targeting Agents 277\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSusan M. Galbraith\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 Introduction 277\u003c\/p\u003e \u003cp\u003e16.2 Methods for imaging tissue blood flow rate 278\u003c\/p\u003e \u003cp\u003e16.3 Central volume theorem 279\u003c\/p\u003e \u003cp\u003e16.4 Kety model 280\u003c\/p\u003e \u003cp\u003e16.5 Fraction of cardiac output or ‘first-pass’ methods 286\u003c\/p\u003e \u003cp\u003e16.6 Color Doppler ultrasonography 286\u003c\/p\u003e \u003cp\u003e16.7 Imaging hypoxia 287\u003c\/p\u003e \u003cp\u003e16.8 Imaging glucose metabolism 288\u003c\/p\u003e \u003cp\u003e16.9 Preclinical experience of imaging vascular-disrupting agents 290\u003c\/p\u003e \u003cp\u003e16.10 Clinical experience of imaging vascular-disrupting agents 293\u003c\/p\u003e \u003cp\u003e16.11 Conclusions 296\u003c\/p\u003e \u003cp\u003eReferences 298\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Clinical Progress in Tumor Vasculature-disrupting Therapies 305\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eAndrew M. Gaya and Gordon J. S. Rustin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17.1 Introduction 305\u003c\/p\u003e \u003cp\u003e17.2 Potential clinical advantages of vascular-disrupting agents 306\u003c\/p\u003e \u003cp\u003e17.3 Biological (ligand-directed) VDAs 306\u003c\/p\u003e \u003cp\u003e17.4 Small-molecule VDAs 307\u003c\/p\u003e \u003cp\u003e17.5 Potential surrogate markers of CA4P activity 314\u003c\/p\u003e \u003cp\u003e17.6 Combination therapy with VDAs 317\u003c\/p\u003e \u003cp\u003e17.7 VDAs in non-malignant diseases 318\u003c\/p\u003e \u003cp\u003e17.8 Conclusions 319\u003c\/p\u003e \u003cp\u003eReferences 319\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Use of Vasculature-disrupting Agents in Non-Oncology Indications 323\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eJoseph C. Randall and Scott L. Young\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18.1 Background 323\u003c\/p\u003e \u003cp\u003e18.2 Age-related macular degeneration (AMD) 325\u003c\/p\u003e \u003cp\u003e18.3 Myopic macular degeneration 327\u003c\/p\u003e \u003cp\u003e18.4 Retinopathy of prematurity 330\u003c\/p\u003e \u003cp\u003e18.5 Proliferative diabetic retinopathy 331\u003c\/p\u003e \u003cp\u003e18.6 Pediatric hemangiomas 332\u003c\/p\u003e \u003cp\u003e18.7 Arthritis 333\u003c\/p\u003e \u003cp\u003e18.8 Psoriasis 334\u003c\/p\u003e \u003cp\u003e18.9 Conclusions 336\u003c\/p\u003e \u003cp\u003eReferences 336\u003c\/p\u003e \u003cp\u003eIndex 341\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Sociology \u0026amp; anthropology [\u003ca title=\"See our other books on Sociology \u0026amp; anthropology\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Sociology%20\u0026amp;%20anthropology%20%5BJH%5D%22\"\u003eJH\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley","offers":[{"title":"Brand New","offer_id":52255225446680,"sku":"9780470012949","price":119.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9780470012949.jpg?v=1781273802","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/vascular-targeted-therapies-in-oncology-hardback-9780470012949","provider":"Freshly Printed Books","version":"1.0","type":"link"}